A Phase I/II Study of Definitive Chemoradiotherapy with Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Advanced Esophageal Cancer.
Yasushi Sato,Hiroyuki Ohnuma,Masahiro Hirakawa,Yutaka Okagawa,Takahiro Osuga,Kazuyuki Murase,Kohichi Takada,Yutaka Kawano,Satoshi Iyama,Tsuyoshi Hayashi,Tsutomu Sato,Koji Miyanishi,Rishu Takimoto,Masayoshi Kobune,Tamotsu Sagawa,Masakazu Hori,Masanori Someya,Koh-ichi Sakata,Tetsuji Takayama,Junji Kato
DOI: https://doi.org/10.1200/jco.2015.33.3_suppl.123
IF: 45.3
2015-01-01
Journal of Clinical Oncology
Abstract:123 Background: Definitive chemoradiotherapy is one of the options for advanced esophageal cancer (AEC). However, AEC patient survival remains unsatisfactory. To investigate a regimen of definitive chemoradiotherapy that exerts good local control of AEC, we performed a phase I/II study to assess the safety and efficacy of triple-drug chemoradiotherapy with docetaxel, 5-fluorouracil, and nedaplatin (DNF-R) that has less adverse events than cisplatin. Methods: Eligible patients had stage II-IVA AEC. Patients received 2 cycles of docetaxel (20, 30, or 40 mg/m2 for dose levels 1, 2, or 3) and nedaplatin (50 mg/m2) on days 1 and 8, and a continuous infusion of 5-fluorouracil (400 mg/m2/day) on days 1-5 and 8-12, with concurrent radiotherapy (on days 1-5, 8-12, and 15-19, total 60 Gy) every 5 weeks. After DNF-R, patients received at least 2 more cycles of DNF. The recommended dose (RD) was determined with a 3 + 3 design. Results: Thirty-one patients were enrolled from July 2010 to April 2013. In the phase I study, the dose-limiting toxicity (DLT) was grade 4 neutropenia, which was observed in all 3 patients at dose level 2.Thus, the RD schedule was level 1. In the phase II study, the 25 eligibles had a median age of 64 (range 56-78; male/female: 21/4), with PS0/1/2 of 13/10/2 and cStage II/III/IVA of 6/10/9. Grade 3/4 acute toxicity included neutropenia (46%), leukopenia (43%), febrile neutropenia (11%), thrombocytopenia (18%), esophagitis (18%), and nausea (11%) during CRT. Grade3/4 late radiotoxicity included 2 cases of esophagostenosis (7%), but they improved by dilatation. Of the 28 patients treated at the RD level 1, including 3 patients of the RD phase I portion, all of them showed response including 23 (82%) CR and 5 PR. The protocol completion rate was 96.4% (27/28). No treatment-related death was observed. The median PFS (1-year PFS: 67.6% and 3-year PFS: 44.8%) and OS were 21 months and 33.2 months, respectively. The 3-year survival rate was 62.5%. Conclusions: DNF-R showed good tolerability and achieved a high CR rate, suggesting that it is a potentially effective therapeutic regimen for AEC. Clinical trial information: UMIN000005446.